Business Wire

Further Growth Sees Crestbridge Head of Institutional Client Operations Move to Luxembourg

Share

Michael Newton, Head of Institutional Client Operations, will move to Luxembourg to support the growth of the Fund Services team, as the firm cements its position as a global market leader in Private Equity and Real Estate.

As Head of Institutional Client Operations, Michael is part of Crestbridge’s senior leadership team. His role has been extended so he is also responsible for growing the fund services offering from Luxembourg, where he will spend four days a week with the remaining time in Jersey, to support the firm’s growing, global fund client base. Michael will continue to oversee client facing activities within the Group’s fund, real estate and corporate services teams with a view to ensuring clients consistently receive the highest possible levels of service.

Michael’s move comes after an incredible year of growth for Crestbridge in Luxembourg, having doubled its team, made three senior hires, and moved to larger premises. This move will strengthen the firm’s client focused, multi-jurisdictional capabilities and is part of an ambitious global growth strategy.

Michael Johnson, Group Head of Institutional Services, said: “This move demonstrates the depth of talent we have to draw on from within the Crestbridge Group. Mike’s expertise, knowledge and work ethic will be invaluable as we continue to grow and support our global client base generate returns for their investors. I am delighted to have him head up our Client Operations delivery and support the growth of the Luxembourg Fund Services team and look forward to his continued contribution as a leader in the global business.”

Crestbridge already represents 90% of the top ten PERE100 and recently supported the close of one of the largest credit deals of the year, with the Bridgepoint and EQT Credit merger.

Michael continued: “Crestbridge’s longstanding presence in Luxembourg and the evolution of our service offering over the past decade initiated by Daniela Klasen-Martin generates significant value to the firm’s global capabilities. As we continue to grow, we are bolstering our business with client-focused, industry veterans. They are asset class experts who can help managers quickly close on large and complex deals, in particular within our specialisms of private equity and real estate.”

Michael Newton has over 20 years' experience in fund services, providing high-quality and efficient administration services to multi-jurisdictional fund investment structures. Since joining Crestbridge in 2017, he has helped both grow the funds business and maintain a focus on the highest levels of client service. Prior to joining Crestbridge, Michael was a Managing Director and Senior Vice President of a global fund administrator and custodian in Jersey, responsible for assets in excess of US$50bn.

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
  • Crestbridge employs over 300 people and has six international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
  • For our regulatory information please see here for more details.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Daniel Jason at Peregrine Communications
tel. +44 (0) 20 3040 0890
e-mail daniel.jason@peregrinecommunications.com

Nicola Nicholson, Head of Marketing at Crestbridge
tel. +44 (0) 1534 835014
e-mail nicola.nicholson@crestbridge.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Brenus Pharma Reports Favorable Tolerability and Clinical Signals in Early Preliminary Results of First-In-Human Study for STC-1010 in Unresectable Metastatic Stage Colorectal Cancer (MSS CRC) Patients6.1.2026 22:00:00 EET | Press release

Brenus Pharma, a clinical stage biotechnology company unlocking the immune system in vivo to fight solid tumors, announced the successful completion of the first dose levels in its ongoing first-in-human study. The multi-center, open-label trial (NCT06934538) is a phase Ia/Ib study designed to evaluate safety, tolerability and preliminary clinical activity of STC-10101 in a first line setting. It will include in vivo analysis of immune and tumor dynamics during dose escalation of treatment and cohort extension to patients with unresectable locally advanced (stage IIIC, T4b) or unresectable metastatic (stage IV) MSS2 colorectal cancer (CRC). Early findings indicate that the first dose levels have been successfully completed with good overall tolerance and no-dose-limiting toxicities observed to date. “We are pleased to report that the safety profile observed to date is good and consistent with our expectations with no DLT,” said Paul Bravetti, CEO of Brenus Pharma. “Moreover, preliminar

SPIE, the International Society for Optics and Photonics, Announces Its 2026 Fellows6.1.2026 21:35:00 EET | Press release

SPIE, the international society for optics and photonics, welcomes 40 Members as new Fellows of the Society in the 2026 cohort. They join their Fellow Member colleagues in being honored for their excellent technical achievements, as well as for their substantial service to the optics and photonics community and to SPIE. Fellows are Members of the Society who have made significant scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging. Since the Society's inception in 1955, more than 1,800 SPIE Members have become Fellows. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106630672/en/ SPIE, the international society for optics and photonics, announces its 2026 Fellows This year’s inductees are high-profile leaders in academia, industry, and government, many of whom are particularly prominent in their support of the optics and photonics community and mentorship of others. “It’

Chemelex Adds Electric Heat Trace Group Ltd.’s SmartTrace Monitoring Platform to its Heat Tracing Portfolio6.1.2026 21:00:00 EET | Press release

Chemelex, a global leader in electric thermal and sensing solutions, today announced the successful completion of its acquisition of substantially all the assets and ongoing operations of Electric Heat Trace Group Ltd. (EHT Group), headquartered in Ontario, Canada. This strategic move marks an exciting start to the new year and reinforces Chemelex’s commitment to delivering smarter, data-driven solutions for industrial heat trace systems. EHT Group is a recognized innovator in heat trace management, offering advanced software, integrated controller solutions, wireless communication modules, and comprehensive field services. Its flagship platform, SmartTrace, is a robust solution available in both cloud-based and on-premises deployments that enables predictive maintenance, minimizes downtime, and provides secure remote monitoring—helping customers achieve greater reliability and operational efficiency. This endeavor will help Chemelex support greater operational efficiencies for our cus

ZIIHERA Plus TEVIMBRA and Chemotherapy: A Potential New Standard for First-Line HER2+ Advanced GEA6.1.2026 20:30:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, including the first interim overall survival (OS) analysis, will be presented as a Late-Breaking Abstract Oral Presentation (#LBA285) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026, from 8:57- 9:07 a.m. PST. HERIZON-GEA-01 met the dual primary endpoint of progression-free survival (PFS), demonstrating statistically significant and clinically meaningful improvements in both experimental arms compared to the control arm. The addition of TEVIMBRA to ZIIHERA and chemotherapy also sho

Siemens and NVIDIA Expand Partnership to Build the Industrial AI Operating System6.1.2026 19:07:00 EET | Press release

CES 2026 - Siemens and NVIDIA today announced a significant expansion of their strategic partnership to bring artificial intelligence into the real world. Together, the companies aim to develop industrial and physical AI solutions that will bring AI-driven innovation to every industry and industrial workflow, as well as accelerate each others’ operations. To support development, NVIDIA will provide AI infrastructure, simulation libraries, models, frameworks and blueprints, while Siemens will commit hundreds of industrial AI experts and leading hardware and software. “Together, we are building the Industrial AI operating system – redefining how the physical world is designed, built, and run - to scale AI and create real-world impact,” said Roland Busch, President and CEO of Siemens AG. “By combining NVIDIA’s leadership in accelerated computing and AI platforms with Siemens’ leading hardware, software, industrial AI and data, we’re empowering customers to develop products faster with the

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye